Key clinical point: The detection of measurable residual disease (MRD) using next-generation sequencing (NGS) has a prognostic value before and 1 month after allogeneic hematopoietic stem cell transplantation (allo-HSCT), depending on the conditioning intensity.
Major finding: In patients receiving myeloablative conditioning, pre-allo-HSCT NGS-MRD detection was associated with posttransplant relapse. Conversely, in patients receiving reduced intensity conditioning 1 month post-allo-HSCT, NGS-MRD was associated with posttransplant relapse (both P less than .001).
Study details: This study included 146 patients with AML who underwent allo-HSCT in complete remission between 2013 and 2018.
Disclosures: This work was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Ministry of Health and Welfare, Republic of Korea. The authors declared no conflicts of interest.
Source: Kim HJ et al. Blood Cancer J. 2021 Jun 4. doi: 10.1038/s41408-021-00500-9 .